Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data

Salvatore D'Angelo, Michele Gilio, Rita M. D'Attino, Giuliana Gualberti, Rocco Merolla, Umberto di Luzio Paparatti, Nazzarena Malavolta, Stefania Corvaglia, Antonio Marchetta, Cinzia Scambi, Nicoletta Romeo, Giorgio Pettiti, Carlo Salvarani, Maria Grazia Catanoso, Raffaele Scarpa, Luisa Costa, Roberta Ramonda, Paola Frallonardo, Maurizio Muratore, Laura QuartaGiuseppe Passiu, Gian Luca Erre, Daniele Lubrano, Enrico Tirri, Marcello Govoni, Federica Furini, Romualdo Russo, Rosario Buono, Maria Rosa Pozzi, Marta Riva, Rosa Daniela Grembiale, Caterina Bruno, Patrizia Gibertini, Antonio Marchesoni

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVES: To describe the baseline characteristics of the patients enrolled in the QUality of life in patients with Axial SpondyloARthritis (QUASAR) study in terms of quality of life (QoL), disease activity, therapy adherence, and work ability in a real-world setting. METHODS: QUASAR is an Italian multicentre, prospective 12-month observational study, including consecutive adult patients classified as axial spondyloarthritis (axSpA) according to the Assessment of SpondyloArthritis international Society criteria for axSpA. RESULTS: Of 512 patients enrolled in 23 rheumatology centres, 80.7% had ankylosing spondylitis (AS) and 19.3% had non-radiographic axSpA (nr-axSpA). Mean ages were 34.1±13.3 years at axSpA symptoms onset and 39.5±13.0 years at diagnosis. Of the patients, 51.4% presented with ≥1 extra articular manifestation (EAM); the most common were psoriasis (17.8%) and uveitis (16.4%). Patients with nr-axSpA and AS had similar EAM rates, disease activity, and QoL. Biologic disease-modifying anti-rheumatic drugs (bDMARDs; 83.2%) were the most commonly received medication, followed by conventional synthetic DMARDs (22.9%) and non-steroidal anti-inflammatory drugs (NSAIDs; 16.6%). At baseline, higher treatment satisfaction was reported with bDMARDs which, together with NSAIDs, were associated with the best overall scores for disease activity, function, and QoL in the overall population and AS subgroup. CONCLUSIONS: QUASAR is the first Italian prospective study that comprehensively evaluated a large axSpA patient sample in a real-world setting. This interim analysis at baseline confirmed that i) patients with AS and nr-axSpA have similar QoL and disease burden, ii) nearly all axSpA patients receive treatment, and iii) bDMARDs and NSAIDs, overall, yield better disease activity and QoL.

Original languageEnglish
Pages (from-to)748-755
Number of pages8
JournalClinical and Experimental Rheumatology
Volume37
Issue number5
Publication statusPublished - Sep 1 2019

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data'. Together they form a unique fingerprint.

Cite this